Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2021

Realising potential combination and personalised therapy

Is there an optimal first-line combination approach for metastatic mRCC?

Date

16 Sep 2021

Session

Realising potential combination and personalised therapy

Topics

Tumour Site

Renal Cell Cancer

Presenters

Toni Choueiri

Authors

T.K. Choueiri

Author affiliations

  • Medical Oncology Department, Dana Farber Cancer Institute, 02215 - Boston/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.